obesity drug news today glp-1 october 2025 Alarming rise in weight loss overdoses Beyond GLP-1: the next wave
Description
Hapca, S
Once-weekly long-acting exenatide formulations have shown promise in significantly improving glycemic control and promoting weight loss in patients with inadequately controlled type 2 diabetes
Compounded medications may use semaglutide as an ingredient but are not FDA-approved as finished products
2011;9:56776 (e1-4)
I want to touch base really quickly on something you said earlier regarding food as pleasure and the joy of eating
GLP-1 receptor agonists were originally developed to treat T2DM and obesity
